Weight Loss Treatment – Mounjaro 7.5mg – Step 3 – £201.49

What is it?

Mounjaro is a prescription medication administered via self-injection, designed to support weight management. It contains tirzepatide, a peptide that helps regulate blood glucose levels and energy balance, thereby reducing appetite and cravings. Targeting specific pathways in the brain, enhances satiety, enabling individuals to feel full for longer periods and reducing hunger. When used in conjunction with a calorie-controlled diet and increased physical activity, it results in significant weight loss. Clinical studies have demonstrated that Mounjaro promotes weight loss beyond the benefits of diet and exercise alone.

Who is Mounjaro for?

Ingredients:

Each 7.5 mg dose contains tirzepatide (7.5 mg in 0.6 mL solution), along with sodium phosphate dibasic heptahydrate, sodium chloride, concentrated hydrochloric acid, sodium hydroxide (for pH adjustment), and water for injection.

Administration Guidelines:

• Prior to this treatment, review the instructions for use (IFU) for guidance on proper administration.
• It can be administered at any time of day, with or without food.
• Injection sites include the abdomen, thigh, or upper arm. Rotate injection sites with each dose.
• Visually inspect your dose before use. The solution should be clear and colourless to slightly yellow. Do not use it if the solution is discoloured or contains particles.

Contraindications:

It is contraindicated in patients with:

• – A personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2.
• – Known hypersensitivity to tirzepatide or any of its excipients.

Precautions and Warnings:

– Injection Site: Injection must be administered in the abdomen, thigh, or upper arm. The injection site and timing may vary without requiring dose adjustments.

– Missed Dose: If a dose is missed and it has been no longer than 4 days, administer the missed dose as soon as possible and proceed with the next scheduled dose. If more than 4 days have passed, skip the missed dose and continue with the regular dosing schedule.

– Change of Injection Day: The day for weekly administration can be adjusted, provided there is a minimum of 3 days between two doses. (≥72 hours).

– Storage: Store the medication in a refrigerator (2°C – 8°C). Do not freeze. Keep it in its original packaging to shield it from light. It may be stored at room temperature, not exceeding 30°C, for up to 21 cumulative days. After this period, the pre-filled pen must be discarded.

– Acute Pancreatitis Risk: Caution is advised for patients with a history of pancreatitis. Stop using it if symptoms of pancreatitis occur.

– Hypoglycemia Risk in Type 2 Diabetes: Monitor for hypoglycemia when using Mounjaro in combination with insulin or insulin secretagogues. Dose adjustments of insulin or other medications may be necessary.

– Gastrointestinal Disorders: For patients with severe gastrointestinal conditions, such as gastroparesis, use it with caution.

– Diabetic Retinopathy: Exercise caution in patients with diabetic retinopathy and ensure appropriate monitoring.

– Pregnancy and Lactation: Use during pregnancy is not recommended due to a lack of sufficient data. It is unclear whether Mounjaro is excreted in human milk, so the potential risks should be carefully considered in relation to the benefits.

– Effects on Driving and Operating Machinery: It is unlikely to impair the ability to drive or operate machinery, but caution is advised when used with insulin or sulfonylurea to prevent hypoglycemia.

Adverse Effects: Potential side effects can include, but are not limited to: 

• – Very Common: Hypersensitivity reactions, hypoglycemia (especially with insulin or sulfonylureas), and dizziness.
• – Common: Nausea, diarrhoea, vomiting, constipation, and fatigue.
• – Uncommon: Hair loss, abdominal pain, and acute pancreatitis.

For a complete list of potential side effects, please consult your healthcare provider.

*Note:

• – (1) Dose-dependent
• – (2) More common in certain populations
• – Fatigue may encompass both general exhaustion and physical weakness.